Please use this identifier to cite or link to this item:
Title: Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway
Authors: MAO, MaoSUDHAHAR, VaradarajanANSENBERGER-FRICANO, KristineFERNANDES, Denise C.TANAKA, Leonardo Y.FUKAI, TohruLAURINDO, Francisco R. M.MASON, Ronald P.VASQUEZ-VIVAR, JeannetteMINSHALL, Richard D.STADLER, KrisztianBONINI, Marcelo G.
Citation: FREE RADICAL BIOLOGY AND MEDICINE, v.52, n.2, p.427-435, 2012
Abstract: Nitroglycerin (GIN) has been clinically used to treat angina pectoris and acute heart episodes for over 100 years. The effects of GTN have long been recognized and active research has contributed to the unraveling of numerous metabolic routes capable of converting GIN to the potent vasoactive messenger nitric oxide. Recently, the mechanism by which minute doses of GIN elicit robust pharmacological responses was revisited and eNOS activation was implicated as an important route mediating vasodilation induced by low GTN doses (1-50 nM). Here, we demonstrate that at such concentrations the pharmacologic effects of nitroglycerin are largely dependent on the phosphatidylinositol 3-kinase, Akt/PKB, and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signal transduction axis. Furthermore, we demonstrate that nitroglycerin-dependent accumulation of 3,4,5-InsP(3), probably because of inhibition of PTEN, is important for eNOS activation, conferring a mechanistic basis for GIN pharmacological action at pharmacologically relevant doses.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/19
LIM/19 - Laboratório de Histocompatibilidade e Imunidade Celular

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)997.97 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.